Impact of adverse drug reactions (ADR) on systemic therapy in patients (pts) with advanced or metastatic renal cell carcinoma (mRCC).

31. Mai 2010

Marschner, N., Münch, A., Blumenstengel, K., Sauer, U., Müller, L., 2010.

Ann Oncol, Abstract 949 21(suppl 8), viii298. doi:10.1093/annonc/mdq525